CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This research study is studying several new investigational drug combinations as a possible treatment for follicular lymphoma.The drugs invo...
Phase 1
Chicago, Illinois, United States and 5 other locations
Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...
Phase 3
Chicago, Illinois, United States and 66 other locations
Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...
Phase 1, Phase 2
Chicago, Illinois, United States and 31 other locations
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas....
Phase 1, Phase 2
Chicago, Illinois, United States and 59 other locations
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic...
Phase 2
Chicago, Illinois, United States and 61 other locations
This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma...
Phase 2
Chicago, Illinois, United States and 59 other locations
treatment of advanced classical Hodgkin lymphoma(HL)...
Phase 3
Chicago, Illinois, United States and 215 other locations
This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.
Phase 2
Chicago, Illinois, United States and 29 other locations
treatment for relapsed or refractory and untreated mantle cell lymphoma (MCL).The names of the study drugs involved in this study are:* Acal...
Phase 1, Phase 2
Chicago, Illinois, United States and 2 other locations
comprise 2 cohorts to assess safety and efficacy of emavusertib in combination with ibrutinib in patients with primary central nervous system lymphoma...
Phase 1, Phase 2
Chicago, Illinois, United States and 36 other locations
Clinical trials
Research sites
Resources
Legal